Technical Analysis for ESPR - Esperion Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 41.39 -6.42% -2.84
ESPR closed down 6.42 percent on Friday, March 22, 2019, on approximately normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
4 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical ESPR trend table...

Date Alert Name Type % Chg
Mar 22 MACD Bearish Centerline Cross Bearish 0.00%
Mar 22 Below Lower BB Weakness 0.00%
Mar 22 Lower Bollinger Band Touch Weakness 0.00%
Mar 22 Oversold Stochastic Weakness 0.00%
Mar 21 Bullish Engulfing Bullish -6.42%
Mar 21 Oversold Stochastic Weakness -6.42%
Mar 20 Calm After Storm Range Contraction -4.15%
Mar 20 Stochastic Reached Oversold Weakness -4.15%
Mar 20 Down 3 Days in a Row Weakness -4.15%
Mar 20 Lower Bollinger Band Touch Weakness -4.15%

Older signals for ESPR ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Get Started for Free!
Configure default chart indicators
Basic chart:

Profile
Esperion Therapeutics, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of therapies for the treatment of patients with low-density lipoprotein cholesterol and other cardiometabolic risk factors. Its products include ETC-1002, an oral molecule therapy that is in Phase IIa clinical trials to treat lipid and carbohydrate metabolic pathways; ESP41091, which is in pre-clinical trials for type 2 diabetes and obesity treatment; and 4WF, a synthetic therapy that is in pre-clinical trials to reverse the deleterious effects of atherosclerosis. The company is based in Plymouth, Michigan.
Biopharmaceutical Medical Specialties Diabetes Obesity Cardiology Cholesterol Gabaa Receptor Positive Allosteric Modulators Low Density Lipoprotein Lipids Lipoproteins Atherosclerosis
Is ESPR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Mar 23 A New ETF For An Untapped Real Estate Market
Mar 21 Esperion Therapeutics Inc (ESPR) President & CEO Timothy M Mayleben Bought $217,400 of Shares
Mar 18 Esperion Announces Late-Breaking Presentation of Final Results of Bempedoic Acid Pivotal Phase 3 Study 2 at the American College of Cardiology 2019 Scientific Sessions
Mar 15 Esperion Therapeutics Inc (ESPR) President & CEO Timothy M Mayleben Bought $243,650 of Shares
Mar 13 Esperion Announces Publication of Bempedoic Acid Study 1 Results in The New England Journal of Medicine
Mar 13 Benzinga's Top Upgrades, Downgrades For March 13, 2019
Mar 12 Did You Miss Esperion Therapeutics’s (NASDAQ:ESPR) Impressive 225% Share Price Gain?
Mar 5 New Research Coverage Highlights Advance Auto Parts, AxoGen, Encana, Federal Signal, Nelnet, and Esperion Therapeutics — Consolidated Revenues, Company Growth, and Expectations for 2019
Mar 4 Esperion Announces Presentation of Bempedoic Acid Pivotal Phase 3 Study 2 Results in a Late-Breaking Clinical Trial Session at the American College of Cardiology 2019 Scientific Sessions
Mar 1 Esperion (ESPR) Reports Wider-Than-Expected Loss in Q4
See more ESPR news...
Indicators
Indicator Value
52 Week High 79.3
52 Week Low 33.06
Average Volume 500,243
200-Day Moving Average 45.8349
50-Day Moving Average 45.5314
20-Day Moving Average 47.0045
10-Day Moving Average 47.343
Average True Range 2.7137
ADX 21.54
+DI 18.7914
-DI 25.2443
Chandelier Exit (Long, 3 ATRs ) 46.7989
Chandelier Exit (Short, 3 ATRs ) 49.5011
Upper Bollinger Band 52.3079
Lower Bollinger Band 41.7011
Percent B (%b) -0.03
BandWidth 22.565499
MACD Line -0.3827
MACD Signal Line 0.4515
MACD Histogram -0.8342
Fundamentals Value
Market Cap 936.9 Million
Num Shares 22.6 Million
EPS -5.77
Price-to-Earnings (P/E) Ratio -7.17
Price-to-Sales 0.00
Price-to-Book 6.37
PEG Ratio -4.32
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 45.94
Resistance 3 (R3) 46.43 45.41 45.18
Resistance 2 (R2) 45.41 44.25 45.16 44.92
Resistance 1 (R1) 43.40 43.54 42.89 42.91 44.67
Pivot Point 42.38 42.38 42.13 42.13 42.38
Support 1 (S1) 40.37 41.22 39.86 39.88 38.11
Support 2 (S2) 39.35 40.51 39.10 37.86
Support 3 (S3) 37.34 39.35 37.60
Support 4 (S4) 36.85